ABSCIENCES (EPA:AB) AB SCIENCE - Liquidity contract
Transparency directive : regulatory news
24/06/2010 17:45
Click here to download pdf version
Paris, June 24th, 2010 - 5.45 pm
AB Science has concluded a liquidity contract
AB Science (ISIN: FR0010557264 - Ticker: AB) has concluded a liquidity contract
with Société Générale Securities.
As of June 23, 2010 and for a period ending at December 31, 2010, renewable by
tacit agreement, AB Science has given the responsibility of the market
stimulation of its shares under the AMAFI charter to Société Générale
Securities through a liquidity contract.
The liquidity contract is then composed of:
- 100 000 euros.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase inhibitors (PKIs),
a new class of targeted molecules whose action is to modify signalling pathways
within cells. Through these PKIs, the Company targets diseases with high unmet
medical needs (cancer, inflammatory diseases and central nervous system
diseases), in both human and veterinary medicines. Thanks to its extensive
research and development capabilities, AB Science has its own portfolio of
molecules. Masitinib, a lead compound, has already been registered in veterinary
medicine in Europe and is pursuing three on-going phases 3 in human medicine in
pancreatic cancer, GIST and mastocytosis.
AB Science is listed on NYSE Euronext Paris (Compartment B) - ISIN: FR0010557264
- Ticker: AB
Further information is available on AB Science's website: www.ab-science.com
Financial Communication & Press Relations
Contacts Citigate Dewe Rogerson:
Agnès Villeret - Tel: +33 1 53 32 78 95 - agnes.villeret@citigate.fr